24.40

0.69% -0.17

Pre-market: 24.41 0.01 +0.04%

Damora Therapeutics Inc (DMRA)

Overview News Price History Discussions Forecast

Damora Therapeutics Inc stock is traded at $24.40, with a volume of 200.86K. It is down -0.69% in the last 24 hours and up +0.00% over the past month. Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Previous Close:

$24.57

Open:

$24.11

24h Volume:

200.86K

Relative Volume:

2.32

Market Cap:

$1.47B

Revenue:

Net Income/Loss:

$-209.84M

P/E Ratio:

-5.3392

EPS:

-4.57

Net Cash Flow:

$-6.73M

1W Performance:

-5.79%

1M Performance:

+0.00%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$23.22

$26.33

1-Week Range:

$23.22

$27.01

52-Week Range:

$16.50

$27.68

Damora Therapeutics Inc Stock (DMRA) Company Profile

Name

Damora Therapeutics Inc

Sector

Healthcare (1110)

Industry

Biotechnology (624)

Phone

(781) 281-9020

Address

221 CRESCENT STREET, WALTHAM

Employee

Twitter

Next Earnings Date

2026-03-18

Latest SEC Filings

DMRA's Discussions on Twitter

Compare DMRA vs VRTX, REGN, ARGX, ALNY, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DMRA Damora Therapeutics Inc	24.40	1.47B	0	-209.84M	-6.73M	-4.57
VRTX Vertex Pharmaceuticals Inc	431.86	109.85B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	760.27	80.38B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	765.43	47.60B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	319.52	42.63B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.03	35.19B	606.42M	-1.28B	-997.58M	-6.403

Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-25-26	Initiated	Evercore ISI	Outperform
Feb-17-26	Initiated	UBS	Buy
Jan-07-26	Initiated	Leerink Partners	Outperform
Dec-01-25	Initiated	Guggenheim	Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Nov-23-20	Initiated	BofA Securities	Buy
Nov-23-20	Initiated	Credit Suisse	Outperform
Nov-23-20	Initiated	SVB Leerink	Outperform

View All

Damora Therapeutics Inc Stock (DMRA) Latest News

Apr 07, 2026

Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat

Apr 07, 2026

Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat

Apr 07, 2026

Apr 01, 2026

Damora Therapeutics (DMRA) awards 1.5M options and 500K RSUs - stocktitan.net

Apr 01, 2026

Insider Jennifer Jarrett joins Damora Therapeutics (DMRA) as director and officer - stocktitan.net

Apr 01, 2026

Damora Therapeutics, Inc. Common Stock (DMRA) 10K Form and Latest SEC Filings 2026 - MarketBeat

Apr 01, 2026

Mar 31, 2026

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Price Up 8.5%What's Next? - MarketBeat

Mar 31, 2026

Did Damora’s New Biopharma Heavyweight Leadership Just Reshape Damora Therapeutics' (DMRA) Investment Narrative? - Sahm

Mar 31, 2026

Mar 30, 2026

Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026 - MarketBeat

Mar 30, 2026

Damora Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Mar 30, 2026

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Mar 30, 2026

DMRA Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI

Mar 30, 2026

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - bitget.com

Mar 30, 2026

New Damora CEO gets 2 million-share hiring package under Nasdaq rule - stocktitan.net

Mar 30, 2026

ETFs Investing in Damora Therapeutics, Inc. Stocks - TradingView

Mar 30, 2026

Mar 29, 2026

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Short Interest Update - marketbeat.com

Mar 29, 2026

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Average Rating of “Moderate Buy” by Analysts - Defense World

Mar 29, 2026

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Average Rating of "Moderate Buy" by Analysts - marketbeat.com

Mar 29, 2026

Mar 28, 2026

DMRA (Damora Therapeutics) PB Ratio : (As of Mar. 28, 2026) - GuruFocus

Mar 28, 2026

Mar 27, 2026

DMRA PE Ratio & Valuation, Is DMRA Overvalued - Intellectia AI

Mar 27, 2026

DMRA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Mar 27, 2026

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Trading Down 9.6%Time to Sell? - MarketBeat

Mar 27, 2026